<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219362</url>
  </required_header>
  <id_info>
    <org_study_id>ORVACS 002</org_study_id>
    <nct_id>NCT00219362</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients</brief_title>
  <acronym>MANON 02</acronym>
  <official_title>A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Objectif Recherche Vaccins SIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Objectif Recherche Vaccins SIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior pilot studies have shown that four monthly injections of ALVAC-HIV (vCP1433) are
      immunogenic in 60% HIV-infected patients with a boosting effect obtained after 1 or 2
      injections followed by a plateau or a decrease of these responses prior to interrupting
      therapy. The goal of the present study is to look for an improved vaccination schedule in
      terms of strength and duration of the HIV-specific immunity induced by the HIV-recombinant
      canary pox vector ALVAC-HIV (vCP1452) by testing a strategy of immunization involving a first
      series of two versus three monthly injections followed by a boost three months later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Manon 02 is a phase II, multicentre, randomized, placebo-controlled study with 3 arms
      comprising 2 steps:

      Step I : Immunization phase from W0 to W24, on HAART

      The immunization will be administered by intramuscular injection :

      Arm A: one injection of vCP1452 at W0, W4, W8 and W20 + HAART, for a total of 4 injections
      Arm B: one injection of vCP1452 at W4, W8 and W20 + HAART, for a total of 3 injections Arm C:
      one injection of placebo at W0, W4, W8 and W20 + HAART, for a total of 4 injections or at W4,
      W8 and W20 + HAART, for a total of 3 injections

      Step II: Post immunization phase from W24 to W48, off HAART

      Discontinuation of antiretroviral therapy (ARV) from W24 to W48 :

      The ARV treatment interruption will be proposed at W24, 4 weeks after the last immunization,
      to patient who had completed their immunization phase and have CD4 cell counts &gt; 350
      cells/mm3 and HIV plasma RNA &lt; 400 cp/ml.

      In order to be able to evaluate the capacity of the immune response to reduce the viral
      replication, a period of 16 weeks of interruption is recommended from W24 to W40.

      Resumption of antiretroviral therapy :

      From W24 to W40 : During this 16 weeks period, in case of a decline of CD4 cell counts below
      250 cells/mm3 or of a loss of CD4 greater than 50% of the baseline value, HAART will be
      restarted.

      From W40 to W48 : HAART should be reintroduced if HIV-1 RNA levels &gt; 50 000 cp/ml on 2
      consecutive measurements at two weeks interval even if the CD4 counts are above 250
      cells/mm3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of the frequency of HIV-specific PBMC (CD4/CD8) at W24 (4 weeks after the last immunization)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Percentage of responders as defined by an increase of at least 0.7 log10 from baseline of the frequencies of HIV-specific PBMC and/or CD4 and/or CD8 T cells four weeks after the last immunization(W24) as measured by ELISpot IFNγ</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Change from baseline of the frequency of HIV-specific PBMC and/or CD4 and/or CD8 T cells at week 4, 6, 8, 12, 20 and 24 in the study arms as measured by ELISpot IFNγ</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Evaluation of the magnitude of CD4 and CD8 T cell response at W4, W6, W8, W12, W20, W24 in the study arms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Evaluation of the immune responses, HIV-specific PBMC and/or CD4 and/or CD8 T cells at W48</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Percentage of patients who generate a primary immune response against the artificial pol/nef sequences present in the vaccine but not in the HIV strain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Evaluation of the immune responses directed to vCP1452 in the study arms at all study point during the immunization phase</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Percentage of patients who do not reach the restart therapy criteria from W24 to W48</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Percentage of patients who remain off therapy at W48</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Evaluation of the safety and tolerability of the vCP1452</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>ALVAC-HIV 4 injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALVAC-HIV 3 injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 4 injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 3 injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>one injection of vCP1452 at W0, W4, W8 and W20</intervention_name>
    <arm_group_label>ALVAC-HIV 4 injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>one injection of vCP1452 at W4, W8 and W20</intervention_name>
    <arm_group_label>ALVAC-HIV 3 injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20</intervention_name>
    <arm_group_label>Placebo - 4 injections</arm_group_label>
    <arm_group_label>Placebo - 3 injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV infection

          -  under potent antiretroviral therapy for more than 6 months

          -  with entry CD4+ counts &gt; 350 cells/mm3 for at least 1 year

          -  plasma HIV RNA &lt; 400 cp/ml for at least the last 6 months

          -  Contraception needed for women

        Exclusion Criteria:

          -  Antiretroviral therapy started with CD4 cell count &gt; 400/mm3

          -  Patients treated at time of primary HIV infection

          -  Patient with past AIDS defining event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Katlama, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Services des maladies infectieuses et tropicales, Hopital de la Pitié-Salpétrière, Université Pierre et Marie Curie, INSERM U720</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses et tropicales, Hopital Pitié-Salpétrière, Pavillon Laveran</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Nolfgang Goethe Universitat Zentrum des Innerin Medizin</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacio Irsi Caixa Retrovirology Laboratory, Hospital Universitari Germans</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicios de Infecciosos, Hospital y clinic Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Autran B, Debré P, Walker B, Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol. 2003 Jun;3(6):503-8. Review.</citation>
    <PMID>12776210</PMID>
  </reference>
  <reference>
    <citation>Autran B, Costagliola D, Murphy R, Katlama C. Evaluating therapeutic vaccines in patients infected with HIV. Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S169-77. Review.</citation>
    <PMID>15285715</PMID>
  </reference>
  <results_reference>
    <citation>Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C; ORVACS Study Group. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS. 2008 Jul 11;22(11):1313-22. doi: 10.1097/QAD.0b013e3282fdce94.</citation>
    <PMID>18580611</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>November 24, 2009</last_update_submitted>
  <last_update_submitted_qc>November 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pr Christine KATLAMA</name_title>
    <organization>Objectif Recherche Vaccins SIDA</organization>
  </responsible_party>
  <keyword>HIV-1 infection</keyword>
  <keyword>therapeutic vaccine</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

